Richard J. Lewis
Corporate Officer/Principal en The University of Queensland .
Cargos activos de Richard J. Lewis
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| The University of Queensland | Corporate Officer/Principal | 01/07/2009 | - |
| National Health & Medical Research Council | Corporate Officer/Principal | 01/07/2009 | - |
Historial de carrera de Richard J. Lewis
Antiguos cargos conocidos de Richard J. Lewis.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Corporate Officer/Principal | 01/07/2009 | - |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Director Técnico/Científico/I+D | 01/01/2000 | - |
| Fundador | 08/02/2010 | - |
Estadísticas
Internacional
| Australia | 4 |
| Estados Unidos | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorial
| Health Technology | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Commercial Services |
| Empresas privadas | 2 |
|---|---|
Xenome Ltd.
Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
| National Health & Medical Research Council | Government |
- Bolsa de valores
- Insiders
- Richard J. Lewis
- Experiencia